Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Drug:
cladribine
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL01
, NCT00198991
2.
German Multicenter Trial for the Treatment of Newly Diagnosed T-Lymphoblastic Lymphoma in Adults
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL04
, NCT00199017
3.
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and under
Sponsor:
Other
Protocol IDs:
BfArM 4022064
, DKH 50-2728, NCT00111345
4.
Phase I/II Study of Vorinostat, Cladribine, and Rituximab in Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
OHSU-4180
, 4180, OHSU-HEM-08002-L, MERCK-OHSU-4180, NCT00764517
5.
Phase I/II Study of Rituximab, Cladribine, and Temsirolimus in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N078D
, N078D, NCT00787969
6.
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CAI
, NCT00126321
7.
2CDA With Rituximab in Hairy Cell Leukemia
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2004-0223
, NCT00412594
8.
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
AGMT_MALT
, EudraCT 2008-000767-41, NCT00656812
9.
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2005-0733
, NCT00492050
10.
Phase II Randomized Study of Cladribine in Combination With Concurrent Versus Delayed Rituximab in Patients With Hairy Cell Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-09-C-0005
, 09-C-0005, NCI-P08372, NCT00781235
11.
Phase I Study of Cladribine, Cytarabine, and Imatinib Mesylate in Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
URCC-U26403
, URCC-RSRB-10427, NOVARTIS-CSTI571AUS161, NCT00258271
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
